FDA Drug Recalls

Recalls / Class II

Class IID-0437-2022

Product

LET Topical Gel, Lidocaine HCL / Epinepherine / Tetracaine HCl, 4%/0.05%/0.5%, 3 mL per syringe, Single Dose Syringe for Topical Use, Edge Pharma, LLC, 856 Hercules Dr. Colchester, VT, NDC 05446-0607-01

Affected lot / code info
07-2021-12@6 12-09-2021, 07-2021-19@7 12-16-2021, 07-2021-26@5 12-23-2021, 08-2021-02@8 12-30-2021, 08-2021-09@10 01-06-2022, 08-2021-13@6 01-10-2022, 08-2021-18@4 01-15-2022, 08-2021-24@8 01-21-2022, 08-2021-30@5 01-27-2022, 09-2021-07@11 02-04-2022, 09-2021-13@5 02-10-2022 & 10-2021-04@9 03-03-2022.

Why it was recalled

CGMP Deviations

Recalling firm

Firm
Edge Pharma, LLC
Notification channel
Press Release
Type
Voluntary: Firm initiated
Address
856 Hercules Dr, Colchester, Vermont 05446-8014

Distribution

Quantity
26917 syringes
Distribution pattern
nationwide

Timeline

Recall initiated
2021-12-06
FDA classified
2022-01-24
Posted by FDA
2022-02-02
Terminated
2023-06-07
Status
Terminated

Source: openFDA Drug Enforcement endpoint. Recall record D-0437-2022. The FDA issues recall classifications as health-hazard assessments, not legal findings; for legal claims consult a licensed attorney.